M&A & Funding Tracker · free with your email

Every cannabis deal since 2017, with the terms behind the headline.

The tracker records 650+ cannabis deals across 22 markets: who bought what, for how much, how it was paid for and what happened next, each figure tied to its source. The whole record is free with your email.

Already have access? Open the tracker →

The trackerUpdated several times a weekNew deals, stage changes and sources are added as they happen. Access is free.
This pageFigures as of 2 Nov 2026A website snapshot. The newest deal counted here is dated 30 Oct 2026, so the tracker is already ahead of it.
From the record2026 passed all of 2025 in September.Cannabis deals recorded in the tracker, added up month by month
202620252024
04080120160JFMAMJJASONDAll of 2025: 1282026 · 1522025 · 1282024 · 117
04080120160JFMAMJJASONDAll of 2025: 128152128117
152deals in 2026, to 30 Oct
+55%on the same date in 2025 (98)
22markets, since 2017
Website snapshot 2 Nov 2026. The tracker itself moves several times a week.

What’s in the tracker

One record of the market, cut every way you need.

Every deal sits on the same schema, so you can slice the whole market by year, country, vertical, supply chain, deal type, stake and stage, see who is most active, and check which fields each record carries. These are the exact counts at the website snapshot of 2 Nov 2026.

Deals recorded, by year
4
16
30
25
77
47
60
117
128
152
2017201820192020202120222023202420252026*
*2026 runs to 30 Oct. Two records carry no date and are left out.
What it shows1522026 is already the biggest year in the record.

By 30 October the tracker held 152 cannabis deals dated 2026, against 128 in the whole of 2025 and 77 in 2021, the last boom. 28 of this year’s deals are debt financings, twice as many as in the whole of 2025, so you see the refinancing wave as well as the takeovers.

  • Filter by year
  • Sort by value
  • Source links
Deals tagged to each market, top 12 of 22
United States255
Canada133
Germany87
United Kingdom74
Australia44
Israel29
Switzerland16
Portugal11
Brazil11
New Zealand10
Spain9
Poland9
A cross-border deal is tagged to every market it touches, so tags add up to more than deals.
What it shows228deal tags in Europe, against 133 for Canada.

The US and Canada still carry the most deals, but Germany (87) and the UK (74) are now the next two markets, and Europe as a whole outnumbers Canada. If you are pricing a European platform, these are your comparables.

  • Filter by market
  • Every country a deal touches
  • Source links
Deals tagged to each market vertical
Medical cannabis371
Recreational cannabis243
CBD / hemp-derived84
Pharmaceutical cannabis61
Cannabis-adjacent25
Hemp24
A deal can sit in more than one vertical, so tags add up to more than deals.
What it shows371deals touch medical cannabis.

Medical is still where most of the money goes: 371 deals against 243 for adult use. Pharmaceutical cannabis, where the approved medicines sit, accounts for 61, and hemp-derived CBD for 84.

  • Filter by vertical
  • Medical vs adult use
  • Pharmaceutical
Deals tagged to each part of the supply chain
Manufacturing / processing295
Cultivation258
Retail216
Distribution / wholesale135
Ancillary / technology42
Genetics / R&D35
Testing / lab3
Segments overlap: a vertically integrated target is tagged to each part it runs.
What it shows351tags for retail and distribution.

Buyers pay for the route to market. Retail and distribution together carry 351 tags, more than cultivation (258). Manufacturing and processing lead on their own, with 295.

  • Filter by segment
  • Vertical integration
  • Source links
Deals by type, 9 types
Acquisition321
Equity raise164
Debt raise58
Asset sale38
Merger24
IPO/Listing23
Distress / restructuring21
Delisting6
Grant / Subsidy2
One record has no type yet and is left out.
What it shows21Distress is now a deal type of its own.

Acquisitions still lead, but the tracker now records creditor protection, receiverships and delistings as deals, because that is where assets change hands. 21 distress records and 6 delistings sit alongside the 321 acquisitions.

  • Filter by type
  • Stake type
  • Disclosed value
Deals by the stake they took
Controlling (>50%)243
Minority (≤50%)128
Full asset86
Partial asset9
Add-on / bolt-on8
Not applicable (raises, debt, listings)121
63 records have no stake type yet.
What it shows69%of deals that buy something buy control.

243 controlling stakes and 86 whole assets, against 128 minority stakes. Where a percentage was disclosed, the record carries it, so you can separate a takeover from a toehold.

  • Stake type
  • Target stake %
  • Filter by control
Every deal by its current stage
53346

533Closed

26Signed

26Milestone

46Announced

27Withdrawn

Stages are the tracker’s own: announced, signed, process milestone, closed, withdrawn.
What it shows98deals are still in motion.

A deal does not end at the press release. 98 records are announced, signed or waiting on a court or a regulator, and 27 are kept as withdrawn, because a database that deletes the deals that died tells you a rosier story than the market had.

  • Filter by stage
  • Closed date
  • Linked news
Companies that appear most often, on either side of a deal
Vireo Growth20
Curaleaf16
The Cannabist Company14
Synbiotic SE13
Aurora13
TerrAscend12
Canopy Growth11
IM Cannabis10
Sanity Group9
Organigram9
High Tide9
SNDL8
Counts appearances as buyer, seller, investor or issuer, not acquisitions made.
What it shows20deals involve Vireo Growth.

No company has been busier: Vireo Growth appears in 20 records, ahead of Curaleaf (16) and The Cannabist Company (14). Every company links to all of its deals, so you can see a buyer’s whole pattern, not one press release.

  • Every party tagged
  • All deals per company
  • Buyer and seller history
Every field on a deal record, and how often it is filledWho
Buyer, target and every party (Partners)76%
Advisors and brokers22%
What
Deal type100%
Market vertical93%
Supply-chain segment93%
Country tags100%
Money
Headline consideration + currency65%
Stake type90%
Target stake %30%
Enterprise value19%
Stated EBITDA (for multiples)2%
Process
Stage100%
Announcement or closing date100%
Closed date9%
Context
Analyst notes: economics, structure, operations, financials, signals88%
Sources
Linked news items98%
Share of the 658 cannabis deals with each field filled. Values are only recorded when they were disclosed.
What it shows16fields on every record.

Each deal carries the same structure: the parties and their advisors, what was bought and where, the money and the stake, the stage and its dates, an analyst’s notes on the economics and structure, and the news behind it. That is what makes the deals comparable.

  • One schema
  • Disclosed values only
  • Analyst notes

Quarter in review · Q3 2026

The busiest third quarter in the record, and what drove it.

July to September 2026 is a closed quarter, so its numbers will not move. Pick a story to see the records behind it: consolidation, insolvency sales, a hostile bid, European platforms and the return of bank lending.

Q3 202643

cannabis deals between July and September, up 43% on Q3 2025 (30) and more than double Q3 2024 (19). No third quarter in the record comes close.

Every third quarter in the record
10
4
17
5
17
19
30
43
’19’20’21’22’23’24’25’26
What kind of deals
Acquisitions15Asset sales7Equity raises10Debt6Distress1Listings1Mergers1Other2
Five stories from the quarter, each one a set of linked records
Consolidation6Vireo Growth transactions in one quarterVireo Growth signed or closed six transactions

No company was busier. Between July and September Vireo signed or closed six transactions, from a single Pennsylvania licence to an all-stock merger with Planet 13. One of them, in Ohio, is itself a package of four deals.

17 JulPhytoNatural / FarmX, Pennsylvania licenceUS$20mClosed
20 JulThe Cannabist Company assets in five states (CCAA sale)up to US$35mSigned
27 JulPlanet 13, all-stock merger: 36 dispensariesstockSigned
31 JulOhio: a four-part package, 8 dispensaries + cultivation~US$208mSigned
7 AugPharmaCann Colorado retail assets~US$49m stockClosed
21 AugC21 Investments, 3 Nevada dispensariesundisclosedClosed
Distress3 of 7asset sales that came out of an insolvencyInsolvency became a source of deals

Three of the quarter's seven asset sales came out of creditor protection, a lender foreclosure or a bankruptcy auction, and two more companies entered or left an insolvency process.

20 JulThe Cannabist Company assets to Vireo (CCAA sale)up to US$35mSigned
27 JulSNDL takes Parallel's FL/TX/MA assets by secured-creditor foreclosure: 56 storesundisclosedClosed
28 JulFinal Bell Holdings: voluntary assignment in bankruptcy Milestone
21 SepSimply Solventless: CCAA exit financingC$1.0m + conversionsSigned
30 SepGriffin Greenhouse: stalking-horse bid for BFG Supply's assetsundisclosedMilestone
Hostile bidUS$5.00per share, after the October raiseCuraleaf went hostile for Aurora

Curaleaf launched a hostile take-over bid for Aurora Cannabis on 11 August at US$4.00 a share, then raised it on 5 October. The bid is still open, so the record carries it at its current stage.

11 AugBid launched at US$4.00 per share Milestone
5 OctRaised to US$5.00: 0.4013 Curaleaf shares + US$1.00 cash Milestone
4 DecBid expiry date Upcoming
EuropeDE · UK · PL · ESmarkets where platforms changed handsEuropean platforms changed hands

Buyers picked up licences and distribution in Germany, the UK and Poland, and Spain got a €14m hemp-fibre plant.

19 AugAurora buys Internode & HAP Pharma, UK pharmacy and import licences£2.1mClosed
11 SepRed White & Bloom takes 62.63% of HEAL Europe (Grünhorn, Leva, Zerenia)undisclosedClosed
14 SepCosma buys 50% of IMP&C, Poland (phase 1)undisclosedMilestone
29 SepIM Cannabis sells its European arm, incl. Adjupharm, to Slil.comC$12.4mClosed
10 SepBioCircular Fiber: hemp fibre plant funding, Dos Hermanas€14mAnnounced
10 JulKombinat Konopny: Emiteo equity raise, PolandPLN 4.4mAnnounced
CreditC$120mof new bank facilities from BMO and TDLenders came back to the table

Canadian banks re-opened credit lines and a cannabis lender financed a whole retail estate.

13 JulChicago Atlantic finances Koach: second lien on 32 retail propertiesUS$62.5mClosed
5 AugHigh Tide: senior secured facilities with BMOC$40mClosed
10 SepCannara Biotech: syndicated facility restated with BMO and TDC$80mSigned

The 20 largest closed M&A deals

The twenty biggest cannabis acquisitions, with their terms open.

Ranked by disclosed value, closed deals only. Open any row to see what was bought, how it was paid for and what it signalled. This is the same depth you get on every record in the free tracker.

#ClosedBuyer → targetMarketValueStakePaid in
1May 2021Jazz Pharmaceuticals → GW PharmaceuticalsUK / USUS$7.2bn100%Cash + stock
What it was

The largest cannabis transaction on record: a pharma company buying an approved cannabinoid medicine.

The terms

US$220 per GW ADS (US$200 cash + US$20 in Jazz shares), a ~50% premium; EV ~US$6.7bn; US$5.35bn of debt raised to fund the cash.

What it signalled

Set the benchmark for what an approved, reimbursed cannabinoid drug is worth.

Advisors on the record: Cravath, Swaine & Moore (GW)
2May 2021Tilray → Aphria (reverse acquisition)CanadaUS$3.9bn100%All stock
What it was

Two Canadian producers combined into the world's largest cannabis company by revenue.

The terms

Aphria holders took ~62% of the combined company, which kept the Tilray name; ~US$78m of annual cost synergies targeted.

What it signalled

The template for Canadian consolidation, and Tilray's route into Europe through Aphria's German network.

3Jul 2018Aurora Cannabis → MedReleafCanadaC$3.2bn100%All stock
What it was

The largest Canadian cannabis merger: two licensed producers combined three months before adult-use legalisation.

The terms

3.575 Aurora shares per MedReleaf share (C$29.44, a ~34% premium); Aurora holders kept ~61% of the combined company.

What it signalled

The top of the Canadian stock-funded roll-up, paid almost entirely in Aurora shares.

Advisors on the record: McMillan, Dorsey & Whitney (Aurora); Stikeman Elliott (MedReleaf); Davies Ward Phillips & Vineberg (MedReleaf shareholders)
4May 2018Aurora Cannabis → CanniMed TherapeuticsCanadaC$1.1bn100%Cash + stock
What it was

The first contested takeover between Canadian licensed producers, ending in a supported deal.

The terms

C$43.00 per share (3.40 Aurora shares, or cash and shares with cash capped at C$140m); CanniMed paid Newstrike a C$9.5m break fee to walk away.

What it signalled

A hostile bid at a C$24.00 cap became a friendly one at nearly double the price in two months.

Advisors on the record: Borden Ladner Gervais (CanniMed)
5Oct 2021Trulieve → Harvest Health & RecreationUnited StatesUS$2.1bn100%All stock
What it was

Created the most profitable US operator by EBITDA.

The terms

0.1170 Trulieve shares per Harvest share; 126 dispensaries in 11 states and 22 cultivation sites at close.

What it signalled

The peak of the 2021 multi-state roll-up.

6Jan 2020Cresco Labs → Origin HouseUS / CanadaUS$730m100%All stock
What it was

Bought California distribution into 575+ dispensaries.

The terms

0.7031 exchange ratio; Origin holders took ~20% of Cresco.

What it signalled

Distribution, not cultivation, was the asset being paid for.

7Jul 2020Curaleaf → Grassroots CannabisUnited StatesUS$700m100%Cash + stock + deferred
What it was

Formed the largest US multi-state operator by footprint.

The terms

Agreed at ~US$875m in July 2019 and cut by ~20% before closing.

What it signalled

Showed the 2019–20 valuation reset in a single deal.

8Feb 2019iAnthus → MPX Bioceutical (US assets)United StatesUS$640m100%All stock
What it was

The first US public-to-public cannabis merger.

The terms

Pro forma EV ~US$1.6bn; MPX's non-US business spun out as MPX International.

What it signalled

iAnthus later defaulted on its senior notes: scale did not fix the balance sheet.

9Mar 2022TerrAscend → Gage GrowthUS / CanadaUS$545m100%All stock
What it was

Made Michigan TerrAscend's largest market.

The terms

0.3 TerrAscend shares per Gage share; 11 dispensaries plus Cookies and Runtz partnerships.

What it signalled

In May 2026 a Michigan court put TerrAscend's Michigan business into receivership.

10Mar 2018Aphria → NuuveraCanadaUS$326m100%Cash + stock
What it was

Became Aphria International, the platform for its push into regulated markets abroad.

The terms

C$0.62 cash + 0.3546 Aphria shares per Nuuvera share; EV ~US$525m.

What it signalled

Questioned by a short-seller over valuation; a C$30m class-action settlement followed in 2025.

11Feb 2021Ayr Wellness → Liberty Health SciencesUnited StatesUS$290m100%All stock
What it was

Ayr's entry into Florida's vertically integrated medical market.

The terms

~29 dispensaries and the Gainesville cultivation campus.

What it signalled

Part of the 2021 race for limited-licence Florida footprints.

12Feb 2020Curaleaf → Cura Partners (Select)United StatesUS$286m100%All stock + contingent
What it was

Bought a leading vape and oil brand rather than licences.

The terms

Signed in May 2019 at ~US$948.8m; cut to 55m shares upfront (~US$286m) plus revenue-linked contingent shares.

What it signalled

The repricing became the case study for 2019's over-valued deals.

13Apr 2021Curaleaf → EMMAC Life SciencesUK / DE / PT / ESUS$286m100%Cash + stock + earn-out
What it was

Curaleaf's entry into Europe: it became Curaleaf International.

The terms

US$50m cash + ~US$236m in shares, up to US$57m of earn-outs; a parallel US$130m investment for 31.5% valued the platform at US$413m.

What it signalled

Gave Curaleaf cultivation and distribution in four European markets.

Advisors on the record: Canaccord Genuity (EMMAC); Torys; Collas Crill
14Dec 2022RIV Capital → EtainUnited StatesUS$247m100%Cash + stock
What it was

A Scotts Miracle-Gro-backed investor became a New York operator.

The terms

~US$212m cash + ~US$35m stock, closed in two stages after regulator approval.

What it signalled

A shareholder went to court over the price; Etain sold US$5.4m in its first nine months under RIV.

15Jun 2021Columbia Care → Green Leaf MedicalUnited StatesUS$240m100%Cash + stock
What it was

Consolidated the mid-Atlantic: Maryland, Pennsylvania, Ohio, Virginia.

The terms

Announced 26 Mar 2021, closed 11 Jun 2021.

What it signalled

Columbia Care later became The Cannabist Company, which entered CCAA in 2026.

16Apr 2026Organigram → Sanity Group (remaining ~91%)Germany€227.2m (max)~91%Cash + stock + fixed deferred
What it was

Organigram bought out its German platform.

The terms

€107.3m upfront (€78.0m cash + €29.3m shares); the up-to-€113.8m earn-out was later fixed at ~€96m, due April 2027.

What it signalled

Five linked records, from the first venture round to the fixed earn-out. Follow it step by step ↓

Advisors on the record: EY, BMO, Goodmans, Hogan Lovells (Organigram); Rothschild & Co (Sanity)
17May 2019Canopy Growth → C3 Cannabinoid Compound Co.Germany€225.9m100%All cash
What it was

Bought what was then Europe's largest cannabinoid pharmaceuticals company.

The terms

~8.3x C3's 2018 revenue of €27.1m.

What it signalled

Canopy sold C3 to Dermapharm in December 2021 at a steep discount.

18Nov 2018Aurora Cannabis → ICC LabsUruguay / ColombiaUS$220m100%All stock
What it was

Bought ~70% of Uruguay's adult-use supply and a Colombian medical base.

The terms

31.9m Aurora shares at 0.2448 per ICC share.

What it signalled

Peak of the Canadian producers' Latin American expansion.

19Apr 2021Cresco Labs → Bluma WellnessUnited StatesUS$213m100%All stock
What it was

Cresco's entry into Florida.

The terms

0.0859 Cresco shares per Bluma share, a ~29% premium.

What it signalled

Operators were paying up for limited-licence medical markets.

20Jun 2021HEXO → Zenabis GlobalCanadaUS$185m100%All stock
What it was

Added 111,200 kg of capacity and 2.1m sq ft of greenhouse.

The terms

0.01772 HEXO shares per Zenabis share.

What it signalled

HEXO itself was absorbed by Tilray in 2023.

Closed cannabis acquisitions, mergers and asset sales, ranked by the tracker’s USD-converted headline value. Values are shown in the deal’s own currency. Website snapshot 2 Nov 2026.Get the other 630+ free →

Follow one deal, end to end

Organigram and Sanity Group: seven years in five records.

Most databases show you the February headline. The tracker shows the venture rounds that came before it, the minority stake that tested the water, the terms, the closing, and the earn-out that was rewritten four months later.

tracker.cannamonitor.com › Companies › Sanity Group › FundingLive
Sanity Group: seven funding rounds before a strategic buyer arrivesEquity · Germany · 2019–2022
Founded2018, Berlin
BrandsVAAY · Endosane
Jun 2021US$44.2m round led by Redalpine
Sep 2022US$37.6m round led by BAT
€1.5mJun 2019
€20.1mFeb 2020
€4mOct 2020
€5mMar 2021
US$44.2mJun 2021
US$3.5mNov 2021
US$37.6mSep 2022
The question it answers

Who funded this company before it was bought?

Seven rounds sit on Sanity's record. Redalpine led the US$44.2m round in June 2021, one of the largest a European cannabis start-up had raised, and British American Tobacco led the round in September 2022. Keep BAT in mind: it turns up on both sides of this deal.

Step 1 of 5
tracker.cannamonitor.com › M&A & Funding › Organigram → Sanity GroupLive
Organigram → Sanity Group: €14m for ~9%Minority stake · Closed · 25 Jun 2024
Instrument€11.5m convertible + €2.5m secondary
Total package€17m incl. supply agreement
Stake~9%
Implied value~€155m
The question it answers

When did the buyer first show its hand?

Two years before the takeover, Organigram bought a minority stake through a convertible loan and a secondary purchase, alongside a supply agreement. The record links it to the later deal, so you can see what the first ticket implied about value.

Step 2 of 5
tracker.cannamonitor.com › M&A & Funding › Organigram → Sanity Group (~91%)Live
Share purchase agreement for the remaining ~91%Acquisition · terms agreed 18 Feb 2026
Upfront, as announced€113.4m (€80.0m cash + €33.4m shares)
Earn-outup to €113.8m (€20.0m cash + €93.8m shares)
Maximum value€227.2m
Share price bandC$3.00 floor, C$4.00 cap
€113.4m upfrontup to €113.8m earn-out
The question it answers

What was the headline, and what sits behind it?

The €227.2m in the press was a maximum: €113.4m upfront plus an earn-out of up to €113.8m tied to Sanity's results over the year to 1 April 2027, most of it payable in Organigram shares. The record keeps the two halves apart, because only one of them was certain.

Step 3 of 5
tracker.cannamonitor.com › M&A & Funding › Organigram → Sanity Group › ClosingLive
Closed: €107.3m paid upfrontAcquisition · Closed · 15 Apr 2026
Upfront€78.0m cash + €29.3m shares
BAT placement€40.3m (C$65.2m)
Bank facilitiesup to C$60m from ATB
AdvisorsEY · BMO · Rothschild & Co
The question it answers

Who paid for it, and how?

The upfront came in at €107.3m, not €113.4m, because it is set on Sanity's cash, debt and working capital at closing. BAT is a shareholder in both companies. At closing it took Organigram shares instead of cash for its Sanity stake and put €40.3m of new money into Organigram, which went towards the cash portion. An ATB term loan covered part of the rest, and the revolving facility can fund the earn-out.

Step 4 of 5
tracker.cannamonitor.com › M&A & Funding › Organigram → Sanity Group › UpdateLive
Earn-out replaced by ~€96m of fixed considerationUpdate to the same deal · 20 Aug 2026
Fixed deferred~€96m (€20m cash + €76m shares)
Due1 Apr 2027, settled by 1 May 2027
Wasup to €113.8m, performance-linked
Record typeSame deal, updated, not a new row
€107.3m paid at closing~€96m fixed, due 2027
The question it answers

What changed after the press release?

Four months after closing, the parties swapped the performance test for a fixed payment. Most databases would show the February headline forever. Here the deal stays one record, and each change is added to it with its source.

Beyond M&A · capital markets

Where the money came from, and where it ran out.

Equity raises, debt, listings and distress sit in the same record as the acquisitions, because each one explains the others: the debt that refinanced the roll-ups, the listings that did not last, the insolvencies that put assets up for sale.

41equity raises dated 2021, the peak year for cannabis equity
29in 2026 so far, the most since 2021
C$5.0bnthe largest cheque on record, Constellation into Canopy
Equity raises by year
1
4
15
15
41
10
12
15
21
29
2017201820192020202120222023202420252026
Cannabis equity raises with a date (one record is undated). 2026 runs to 30 Oct.
C$5.0bn38% stake · Nov 2018
Constellation Brands into Canopy Growth

The largest alcohol-into-cannabis investment. Warrants could have taken it to ~55%; the stake was later written down.

C$2.4bn45% stake · Mar 2019
Altria into Cronos Group

Tobacco's biggest cannabis bet. The warrant for more shares was abandoned, leaving ~41%.

US$350mat US$3.75bn · Oct 2021
D1 Capital, Tiger Global and others into Dutchie

Record cannabis-software round, ~83x trailing ARR. The January 2024 round valued Dutchie at US$400m, 89% lower.

US$345mfollow-on · Oct 2018
A Nasdaq follow-on offering into GW Pharmaceuticals

Raised to launch Epidiolex in the US after FDA approval. Jazz bought GW for US$7.2bn in 2021.

C$221m19.9% stake · Mar 2021
British American Tobacco into Organigram

Priced at a premium and kept just under 20%. Five years later BAT helped fund Organigram's purchase of Sanity.

28debt deals in 2026 to 30 Oct
14in the whole of 2025
16in every year before 2025, added together
Debt deals by year
1
0
2
2
3
2
1
5
14
28
2017201820192020202120222023202420252026
Notes, term loans, revolvers and convertibles.
What cannabis pays to borrow: coupons on the record
Ascend WellnessUS$235m · Jul 2024 · senior secured notes
12.75%
CuraleafUS$500m · Feb 2026 · senior secured notes, due 2029
11.5%
TrulieveUS$200m · Dec 2025 · senior secured notes, due 2030
10.5%
Agrify ← Green ThumbUS$20m · Nov 2024 · secured convertible note
10%
The Cannabist CompanyUS$25.75m · Mar 2024 · convertible debentures, due 2027
9%
Vireo GrowthUS$60m · Oct 2026 · real-estate loan, due 2034
8.5%
Cresco LabsUS$50m · Jun 2026 · bank revolver (Needham), to 2030
7.99%
Who is lending
Needham BankCresco · Verano · Standard Wellness
Chicago AtlanticVerano · Koach · S1 Enterprises
BMOHigh Tide · Cannara · Auxly
TD BankCannara
Deutsche BankEnua (€25m, Germany)
NABCann Group (A$55.6m, Australia)
4 of 6European cannabis listings from 2021 have since delisted, gone into administration or liquidated
23listings, IPOs and SPACs on the record
6delistings, the newest deal type in the tracker
A selection from the record, by year
StenocareSpotlight, DK
MGC PharmaceuticalsLSEKanaboLSECellular GoodsLSECannovumDüsseldorfOxford Cannabinoid Tech.LSEGlass House BrandsSPAC, NEOYooma WellnessAQSE
LeaflySPAC, NasdaqAkandaNasdaqBright GreenNasdaqCantourageFrankfurt
Cilo CybinJSE
Cannara BiotechTSXKombinat KonopnyNewConnectTrulieveNYSE
2018
2019
2020
2021
2022
2023
2024
2025
2026
Clever LeavesNasdaqArgent BioPharma (ex-MGC)LSE
Oxford Cannabinoid Tech.LSECeladonLSEAnanda DevelopmentsAQSE
DanCann PharmaSpotlight
Listed in EuropeListed elsewhereDelisted
In the pipeline now
Glass House BrandsNYSE uplisting under way
Ascend Wellnessreverse split for a US uplisting
Innocan PharmaNYSE American listing announced
Spring SciencesASX IPO in process
Distress and restructuring19

companies on the record have been through creditor protection, receivership, administration or bankruptcy since 2023. Seven of the 21 records are from 2026 alone. Their assets end up in other companies’ acquisitions, which is why they sit in the same tracker.

Distress records by year
1
5
8
7
2023202420252026
Creditor protection5
The Cannabist CompanyUS/CA

Assets in five states sold to Vireo

CCAA + Chapter 15 · opened Mar 2026 · latest Jul 2026
Entourage HealthCA

Court-ordered sale process

CCAA · opened Jun 2026 · latest Jun 2026
THC BiomedCA

Filed: C$21.65m liabilities vs C$10.67m assets

CCAA · opened Apr 2026 · latest Apr 2026
Noya HoldingsCA

Creditor protection proceedings

Creditor protection · opened Nov 2024 · latest Nov 2024
Atlas Global BrandsCA

Creditor protection, EY as monitor

CCAA · opened Jun 2024 · latest Jun 2024
Receivership or administration6
TerrAscend (Michigan)US

Court-ordered; US$210m owed to FocusGrowth

Receivership · opened May 2026 · latest May 2026
Helius TherapeuticsNZ

Voluntary administration

Administration · opened Mar 2026 · latest Mar 2026
KanaboUK

Administrators appointed

Administration · opened Nov 2025 · latest Nov 2025
CannasouthNZ

Receivers appointed

Receivership · opened May 2025 · latest May 2025
Greenfern IndustriesNZ

Receivers appointed

Receivership · opened Feb 2025 · latest Feb 2025
Item 9 LabsUS

Receiver appointed by Arizona court

Receivership · opened Jul 2023 · latest Jul 2023
Bankruptcy or liquidation4
Final Bell HoldingsCA/US

Voluntary assignment in bankruptcy

Bankruptcy · opened Jul 2026 · latest Jul 2026
Bazelet / Bazalt PharmaIL

Bankruptcy proceedings

Bankruptcy · opened Dec 2025 · latest Dec 2025
CannovumDE

Liquidation and wind-down

Liquidation · opened Feb 2025 · latest Feb 2025
Hellenic DynamicsUK

Liquidation petition

Liquidation · opened Nov 2024 · latest Nov 2024
Came out the other side4
Mera CannabisCA

Exited; operating companies sold

CCAA · opened Oct 2025 · latest May 2026
BZAMCA

CCAA exit and bankruptcy resolution

CCAA · opened Feb 2024 · latest Oct 2025
Freedom CannabisCA

Restructuring complete

CCAA · opened Apr 2025 · latest Apr 2025
Galaxie BrandsCA

Restructuring complete

CCAA · opened Dec 2024 · latest Dec 2024

The deal pipeline

How many announced deals actually close?

Every M&A deal carries its stage, from announced to closed or withdrawn. Switch between the whole record and the deals announced since January 2025, which are still working their way through.

Where each M&A deal stands today, all years
All M&A dealsacquisitions, mergers, asset sales383
Announcedmade public, nothing signed21
Signedbinding agreement20
Process milestonecourt, regulator or vote pending11
Closedcompleted306
Withdrawnterminated or abandoned25
All years80%of M&A deals on the record have closed.

52 are still open, waiting on a signature, a court or a regulator, and about one in 15 has been withdrawn. The tracker keeps every one of them, with the date the stage changed and the source that changed it.

Where each M&A deal stands today, since 2025
All M&A dealsacquisitions, mergers, asset sales159
Announcedmade public, nothing signed18
Signedbinding agreement15
Process milestonecourt, regulator or vote pending11
Closedcompleted105
Withdrawnterminated or abandoned10
Since 202566%of M&A deals on the record have closed.

44 are still open, waiting on a signature, a court or a regulator, and about one in 16 has been withdrawn. The tracker keeps every one of them, with the date the stage changed and the source that changed it.

Deals that fell apart, and stay on the record
Oct 2019MedMen → PharmaCannUS$682m

All-stock acquisition terminated

Mar 2022Cresco Labs ↔ Columbia CareUS$2.0bn

Agreed merger, terminated July 2023

Feb 2022Verano → Goodness Growth~US$413m

All-stock acquisition withdrawn

Aug 2022Ascend Wellness → MedMen New YorkUS$88m

Terminated

Dec 2025Curaleaf → Cannabist (Virginia)US$110m

Fell away; the assets sold to a Millstreet affiliate for US$130m two months later

May 2026SNDL → 1CM (27 Ontario stores)undisclosed

Terminated over regulatory delays

Ongoing deals
Still open · the biggest live contestCuraleaf → Aurora CannabisHostile take-over bid
11 Aug 2026Bid launchedUS$4.00 per Aurora share
5 Oct 2026Bid raisedUS$5.00: 0.4013 Curaleaf shares + US$1.00 cash

Aurora is a Canadian producer with medical sales in Germany, the UK, Poland, Australia and New Zealand, so the bid touches nine markets on the record.

Other deals still in motion
27 Jul 2026Vireo Growth ↔ Planet 13, all-stock merger: 36 dispensariesUnited StatesstockSigned
31 Jul 2026Vireo Growth → Ohio package: 8 dispensaries + a cultivation siteUnited States~US$208mSigned
26 Aug 2026JARS Cannabis → Sonoran Roots: 27 dispensaries, Arizona's largest retail networkUnited StatesundisclosedSigned
30 Apr 2026Vireo Growth → FLUENT, all-stockUnited StatesstockSigned
12 Mar 2026MG Health ↔ Canify: planned merger into one medical platformGermanyundisclosedAnnounced
5 Jan 2026Wyld → Grön: a North American edibles platformUnited StatesundisclosedSigned
14 Sep 2026Cosma → IMP&C, phase 1 (50%)PolandundisclosedMilestone
29 Jun 2026Tilray Brands → HelloMD Canadian medical assetsCanadaundisclosedMilestone
19 Oct 2026Ewing Morris → Decibel Cannabis: partial cash offer at C$1.91CanadaC$5mAnnounced
52 M&A deals were open at the website snapshot. The tracker updates their stage as each one moves.

What you get

Free gets you every deal. Decide gets you everything around it.

The tracker is free and complete: every deal, every field, every source. Decide is the platform it sits in, where each deal connects to the companies behind it, their financials, the market it buys into and our analysis of what it means.

Free with your email

The deal record

Everything about the transaction itself.

  • Every one of the 650+ deals since 2017
  • All 16 fields on each record, from parties and advisors to stake and stage
  • Filters by year, market, vertical, segment, type, stake and stage
  • The news and sources behind each deal
  • Stage changes as they happen: signed, closed, renegotiated or withdrawn
Get free access →
Decide · €1,420/yr

Everything around the deal

The companies, the money, the markets and the analysis, all linked to the same records.

🏢1,050+companiesCompanies database

A profile for every buyer, seller and investor on the tracker, with their deals, financials, products, trials and news on one page.

📊600+financial filingsEarnings database

Revenue, EBITDA, cash and debt over time, so you can check what a buyer could afford and what a target was earning.

🧭5connected trackersEvery tracker, not just M&A

M&A & Funding, clinical trials (2,300+), regulation (270+ briefs across 118 authorities), market data (50+ databases) and 10,000+ classified news items, all linked to the same companies.

🌍125+countriesCountry dashboards

Patients, prices, imports, licences and rules for each market, so a deal is read against the market it buys into.

🔎125datapacksAnalyst insights

Deep dives such as our analysis of the Dutch Wietexperiment, the pilot behind Cronos's CanAdelaar deal, with the data behind every chart.

📁800+source documentsSources and documents

Filings, decrees and reports, stored and linked to the records they support.

One deal, followed into Decide
1 · The dealM&A & Funding · freeCronos Group → CanAdelaar

€57.5m base price plus cash earn-outs; 100%; closed 15 Oct 2026; 4 linked news items.

→
2 · The buyerCompanies + Earnings · DecideCronos Group

Cronos: FY2025 revenue US$146.6m and US$832m of cash to fund the deal. Every Cronos deal, filing and product on one profile.

→
3 · The marketNetherlands dashboard · DecideThe Dutch Wietexperiment

The Dutch Wietexperiment: 10 municipalities, ~1.7m of 18.1m residents, 10 licensed producers.

→
4 · The analysisInsights · DecideWhat CanAdelaar is worth to Cronos

~1.4x net revenue and ~2.9x adjusted EBITDA at closing, on 1H 2026 annualised results. 540,000 sq ft greenhouse in Voorne aan Zee; ~20,000 kg of flower a year; supplies nearly all 69 pilot coffee shops.

Freewith your emailEssentialsstay currentDecidego deep
The full M&A & Funding Tracker: every deal, every field, filters and sources✓✓✓
Updated several times a week, with every stage change dated✓✓✓
News stream–✓✓
Monthly M&A recap across 30+ markets–✓✓
Insight deep-dives on specific deals–✓✓
Companies database: 1,050+ profiles linked to their deals––✓
Earnings database: 600+ financial filings––✓
Clinical-trial, regulatory and market-data trackers––✓
Country dashboards for 125+ countries––✓
125 analyst datapacks, with the data behind every chart––✓
EV / EBITDA multiples––✓
PriceFree€14.2/moor €142/yr€1,420/yrextra seats €420
Need custom datasets, exports or an integration with your own systems?See Enterprise →
The problem

You can find most cannabis deals. You just can't reliably compare them.

Cannabis deal news is everywhere; comparable deal data is not. So the simple questions stay unanswerable. Five things stop news from being usable data — here's how the Cannamonitor Deal Tracker fixes each.

Each problem, and the fix. Tap to expand ↓

Problem 1Deals are unclassified
Cannamonitor Deal Tracker — pre-classified

Every deal is tagged by vertical, country, type and stage, so the whole market is filterable instead of a pile of headlines. Pull "all medical-cannabis M&A in Germany since 2023" in seconds.

Every deal tagged
Problem 2Currencies don't match
Cannamonitor Deal Tracker — USD-normalised

Every figure is converted to USD at a stated FX basis, so a German raise and a US acquisition compare like-for-like.

12 currencies normalised
Problem 3The headline isn't the price
Cannamonitor Deal Tracker — consideration split

Upfront, earn-out and equity broken out, so you see what was actually paid — not the press-release number.

·· % of deals carry earn-outs
Problem 4Deal stage is ambiguous
Cannamonitor Deal Tracker — explicit stage

Each deal is tracked LOI → signed → closed, with no double-counting of the same transaction across announcements.

Problem 5Sources are scattered or paywalled
Cannamonitor Deal Tracker — source-linked

Every entry links to its original filing, release or regulatory document — open, verifiable and citable.

550+ source links

How the record is kept

One deal, one record, and every change dated.

1 rowOne deal, one record

When a deal is signed, closed, renegotiated or abandoned, the change is added to the same record with its date and source. Organigram and Sanity is one deal with five dated updates, not five deals.

98%Linked to the news behind it

647 of the 658 cannabis deals link to at least one item in our news database, so you can read what was said at the time.

65%Disclosed values only

427 deals carry a disclosed value. The rest are marked undisclosed. We never estimate a price and present it as fact.

658Judged at the asset

Of 695 records, 658 are cannabis deals. A cannabis company buying a brewery is recorded, then excluded from every figure on this page.

Methodology · the trust layer

How we build it.

Every record follows the same rules — no exceptions.

One record, tracked over time

Each deal is a living record, not a one-off headline. We follow it across its lifecycle — rumour → LOI → signed → closed (or collapsed) — and keep the history back to 2017, so you see how terms, parties and valuations actually evolved.

Financially sense-checked

Every figure is normalised to USD at a stated FX basis and pressure-tested for coherence: upfront vs earn-out vs equity split out, multiples computed consistently, outliers queried against filings. Disclosed only — never estimated silently

Authoritative sources, cross-validated

Built only from high-quality, authoritative open sources — regulatory filings, exchange disclosures, official releases — with every material fact corroborated across multiple independent sources before it's logged. Each entry links back to the original.

Analyst-curated nuance

Humans add the judgment a scraper can't: cannabis relevance judged at the asset level (a cannabis operator buying a drinks brand is logged as non-cannabis), deal types disambiguated, edge cases reasoned. Nothing enters without review.

Free · email accessGet the full tracker. It’s free.

Every one of the 650+ deals, every field, filters and the source behind each figure, updated several times a week. Just your email, no card.

Form not loading? Open it in a new tab →

Already have access? Open the tracker →

Questions

What people ask before they sign up.

Anything else? Get in touch →

Yes. Your email unlocks the whole deal record: every deal, every field, the filters and the sources. The paid plans add ongoing news and analysis (Essentials) and the company, market and financial layer behind each deal (Decide).
The tracker itself is updated several times a week, as deals are announced, signed, closed or abandoned. This page is different: it is a snapshot of the tracker, taken on 2 Nov 2026, and the newest deal counted on it is dated 30 Oct 2026. By the time you read this, the tracker will already be ahead of the page.
Acquisitions, mergers and asset sales, equity and debt raises, listings and delistings, grants, and since 2026 distress and restructuring events such as creditor protection or receivership, because that is where assets change hands. A deal is in the figures only if the asset itself is cannabis: a cannabis company buying a brewery is recorded but left out.
The change goes onto the same record, with its date and its source. A renegotiated price, a closing, a fixed earn-out or a termination never becomes a second deal, so the counts on this page are deals, not headlines.
They stay on the record, marked withdrawn: 27 of them today. A database that quietly deletes collapsed deals tells you a rosier story than the market actually had.
Every value is the disclosed one, in the deal’s own currency, with the source attached. If a price was never made public, the record says undisclosed. We do not estimate it and present the estimate as fact.
A model can summarise the news it has seen. It cannot hand you 650+ deals on one schema, with every stage change dated and every figure tied to its source, which is what you need when the number goes into a valuation or a board paper.

The deal record is free. The context is in Decide.

Start with every deal and its terms, free with your email. When you need the company, the market and the numbers behind a deal, everything on this page is connected in Decide, with 125+ markets beside it.

Already have access? Open the tracker →